FDA provided guidance for future registration trial design and for a potential shorter regulatory pathway for developing DPX-Survivac as a monotherapy in certain ovarian cancer patients DARTMOUTH, ...
VANCOUVER, BC, Dec. 17, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (BVAXF) ("BioVaxys" or the "Company") is pleased to announce that in anticipation of restarting clinical studies of various DPX ...
* Launch of DPX-NEO program to develop neoepitope immunotherapies to expand immuno-oncology applications for depovax-based vaccines Source text for Eikon: Further company coverage: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results